VAXCYTE, INC. Debt Securities, Available-for-sale, Unrealized Loss Position
VAXCYTE, INC. (PCVX) had Debt Securities, Available-for-sale, Unrealized Loss Position of $1.80 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $1.80B.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $1.60B.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $300.00M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $800.00M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $1.80B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.60B 10-Q · filed 2026-05-06 |
| 2025-12-31 | $300.00M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $800.00M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $1.30B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $1.20B 10-Q · filed 2025-05-07 |
| 2024-12-31 | $1.50B 10-K · filed 2026-02-24 |
| 2023-12-31 | $654.70M 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |